首页 产品中心
  • FAK Inhibitor 14

    • 1,2,4,5-tetraaminobenzene tetra hydrochloride;FAK inhibitor Y15;Y15
    货号: abs814908
    CAS号: 4506-66-5
    分子式: C6H10N4•4HCl
    分子量: 284.01
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs814908-10mg 1-2周 ¥441.00
    - +
    abs814908-50mg 1-2周 ¥992.00
    - +
    大包装询价
    产品描述
    描述

    Y15 is a small-molecule FAK scaffolding inhibitor that directly inhibits FAK autophosphorylation in a dose- and time-dependent manner.

    纯度
    98%
    使用方法
    Solutions should be used with the same day they are made. If needed, aliquot and store at -20°C for up to a month.
    储存/保存方法
    Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    形态
    Solid
    基本信息
    别名
    1,2,4,5-tetraaminobenzene tetra hydrochloride;FAK inhibitor Y15;Y15
    外观
    faint purple to dark brown powder
    可溶性/溶解性
    DMSO :56 mg/mL (197.18 mM)

    Water :56 mg/mL (197.18 mM)
    生物活性
    靶点
    FAK
    In vitro(体外研究)
    Y15 treatment in vitro results in decreased cell viability, increased detachment, and increased apoptosis in colon cancer cells, breast cancer cells, and melanoma. In TPC1, BCPAP, K1 and TT cell lines, Y15 inhibits pY397 and total FAK expression in a dose-dependent manner. It causes effective dose-dependent detachment in all thyroid cancer cell lines. Y15 causes dose-dependent decrease of colony formation in all papillary thyroid cancer cell lines and increases necrosis in papillary and medullary thyroid cancer cell lines. Y15 does not target homologous Pyk-2, c-Src, c-RAF, EGFR, IGFR, PDGFR, PI3K, VEGFR-3, and c-Met.
    In vivo(体内研究)
    Y15 blocks breast, pancreatic and neuroblastoma tumor growth in vivo. The pharmacokinetics study in mice demonstrates that, following intraperitoneal administration at 30 mg/kg dose, Y15 is very rapidly absorbed in mice, reaching maximum plasma concentration in 4.8 min. Y15 rapidly metabolizes in mouse and human liver microsomes with half-life t1/2 of 6.9 and 11.6 min, respectively. The maximal tolerated dose of single-dose administration of Y15 by oral administration is 200 mg/kg, and the multiple maximum tolerated dose of Y15 is 100 mg/kg by PO during 7 day study. Y15 does not cause any mortality or statistically significant differences in the body weight at 30 mg/kg by IP during 28-day study, and at 100 mg/kg by PO during the 7-day study. There are no clinical chemical, hematological, or histopathological changes in different mice organs at 30 mg/kg by IP during 28 days and at 100 mg/kg dose by PO during 7 days.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
    • 实验方法 实验条件
      0张,还能上传 8 提交
          提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
          提交不成功?请联系info@absin.cn。
          我要提问

      促销资讯 更多

        订购信息
        您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
        GO
        • 0